Significant advancements have been made in working out novel business models for digital health products, but implementing a successful go-to-market strategy remains a major challenge.

We have seen a lot of trial and error, as well as migration between commercialization pathways. One of the critical crossroads on that pathway is whether companies should take the approach of delivering a service, a product, or a bit of both?

Each has pros and cons. A number of digital health products take a service approach, while traditional prescriptions are a product, which adds a layer of complexity to getting these to market.

At HealthXL’s next Global Gathering in Chicago, startups, pharma, and investors will break down the issues around the different approaches to getting a digital health product to market. ‍

We will split up into several roundtables, with each tackling one of the following topics: